Orchestra BioMed Holdings (OBIO) Consolidated Net Income (2021 - 2026)

Orchestra BioMed Holdings (OBIO) has 6 years of Consolidated Net Income data on file, last reported at -$24.8 million in Q1 2026.

• On a quarterly basis, Consolidated Net Income fell 27.72% year-over-year to -$24.8 million in Q1 2026; TTM through Mar 2026 was -$60.5 million, a 22.77% increase from a year earlier, with the FY2025 full-year figure at -$160.1 million, down 1.18% from the prior year.
• Consolidated Net Income for Q1 2026 stood at -$24.8 million, down from $6.4 million in the prior quarter.
• Over the last five years, Consolidated Net Income for OBIO reached as high as $6.4 million in Q4 2025 and fell as low as -$25.2 million in Q2 2024.
• Historically, Consolidated Net Income has averaged -$14.8 million across 5 years, with a median of -$16.1 million in 2024.
• Across the five-year window, Consolidated Net Income slumped 8300.5% in 2022 and jumped 139.71% in 2025, its largest moves.
• Year by year, Consolidated Net Income stood at -$10.2 million in 2022, then decreased by 20.09% to -$12.2 million in 2023, then sank by 31.95% to -$16.1 million in 2024, then jumped by 139.71% to $6.4 million in 2025, then tumbled by 487.22% to -$24.8 million in 2026.
• Per Business Quant data, the three most recent Consolidated Net Income figures were -$24.8 million in Q1 2026, $6.4 million in Q4 2025, and -$20.5 million in Q3 2025.